Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an update.
Neuren Pharmaceuticals Limited has announced an update on its ongoing on-market buy-back program. As of May 16, 2025, the company has repurchased a total of 3,357,012 ordinary fully paid securities, including 40,511 securities bought back on the previous day. This buy-back initiative is part of Neuren’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological conditions. The company is listed on the Australian Securities Exchange under the code NEU and is involved in the research and commercialization of treatments for brain-related disorders.
Average Trading Volume: 777,965
Technical Sentiment Signal: Buy
Current Market Cap: A$1.57B
See more insights into NEU stock on TipRanks’ Stock Analysis page.